IP Library › Granted Patent US 8,530,466
Granted Patent B2
US 8,530,466 · App. 12/867,928 · Granted Sep 10, 2013

Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,530,466
App. No.
12/867,928
Granted
Sep 10, 2013
Kind
B2
Abstract

Novel methods and compositions for the prevention and treatment of all forms of atherosclerosis with 2,4-pyrimidinediamine compounds are described. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.

Claims (1)

1. A method of treating atherosclerosis or regressing or decreasing formation of arterial atherosclerotic lesions, said method comprising administering to a mammal having atherosclerosis an effective amount of N4-(2,2-dimethyl-4-[(dihydrogen phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine or a salt thereof.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2013
From: MASUDA, ESTEBAN; SCHMITZ, JOCHEN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 029832/0576 →